HC Wainwright Lifts Earnings Estimates for PDS Biotechnology

PDS Biotechnology logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright raised its FY2026 EPS estimate for PDS Biotechnology to a loss of $0.44 per share from a loss of $0.49, while maintaining a “Buy” rating. Its forecasts include losses of $0.18 per share in FY2027 and $0.14 in FY2028.
  • PDS Biotechnology reported a quarterly loss of $0.11 per share, missing the consensus estimate of a $0.09 loss by $0.02.
  • Analyst views are mixed: MarketBeat reports an average “Hold” rating and a $9.50 consensus price target, with two analysts rating the stock Buy and one rating it Sell.
  • MarketBeat previews top five stocks to own in December.

PDS Biotechnology Corporation (NASDAQ:PDSB - Free Report) - HC Wainwright lifted their FY2026 EPS estimates for PDS Biotechnology in a note issued to investors on Friday, November 13th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.44) for the year, up from their prior forecast of ($0.49). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for PDS Biotechnology's current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for PDS Biotechnology's Q4 2026 earnings at ($0.07) EPS, FY2027 earnings at ($0.18) EPS and FY2028 earnings at ($0.14) EPS.

PDSB has been the topic of a number of other research reports. Wall Street Zen upgraded shares of PDS Biotechnology from a "sell" rating to a "hold" rating in a report on Monday, October 5th. B. Riley Financial reissued a "buy" rating and issued a $4.00 price objective (up from $3.00) on shares of PDS Biotechnology in a research report on Thursday, October 29th. Finally, Weiss Ratings upgraded PDS Biotechnology from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, September 28th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $9.50.

View Our Latest Research Report on PDS Biotechnology

PDS Biotechnology Price Performance

PDSB opened at $0.89 on Wednesday. PDS Biotechnology has a twelve month low of $0.20 and a twelve month high of $1.79. The company has a quick ratio of 0.57, a current ratio of 0.57 and a debt-to-equity ratio of 2.73. The company has a fifty day simple moving average of $1.01 and a 200 day simple moving average of $0.84.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last announced its earnings results on Friday, November 13th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02).

Hedge Funds Weigh In On PDS Biotechnology

A number of institutional investors have recently made changes to their positions in the business. Commonwealth Equity Services LLC increased its stake in PDS Biotechnology by 26.9% during the third quarter. Commonwealth Equity Services LLC now owns 117,997 shares of the company's stock valued at $89,000 after purchasing an additional 25,000 shares during the last quarter. StoneX Group Inc. bought a new position in shares of PDS Biotechnology in the 3rd quarter worth about $28,000. Everhart Financial Group Inc. bought a new position in shares of PDS Biotechnology in the 3rd quarter worth about $29,000. Renaissance Technologies LLC lifted its position in shares of PDS Biotechnology by 25.0% in the 1st quarter. Renaissance Technologies LLC now owns 220,800 shares of the company's stock worth $134,000 after buying an additional 44,100 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of PDS Biotechnology in the 2nd quarter valued at about $60,000. 26.84% of the stock is owned by institutional investors and hedge funds.

PDS Biotechnology Company Profile

(Get Free Report)

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company developing immunotherapies designed to stimulate the immune system to fight cancer. The company's research focuses on treatments for HPV-associated cancers and other solid tumors. Its pipeline includes PDS0101, an investigational immunotherapy targeting cancers associated with human papillomavirus 16 (HPV16). The candidate uses the company's Versamune platform and is being studied in clinical trials, including in combination with other cancer treatments.

Read More

Earnings History and Estimates for PDS Biotechnology (NASDAQ:PDSB)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in PDS Biotechnology Right Now?

Before you consider PDS Biotechnology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PDS Biotechnology wasn't on the list.

While PDS Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines